Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 44Lenalidomide 29Bortezomib 23daratumumab 22pomalidomide 19Cyclophosphamide 15carfilzomib 14Specimen Handling 14Biopsy 14Calcium Dobesilate 12Magnetic Resonance Spectroscopy 10talquetamab 9isatuximab 9Melphalan 8iberdomide 7fludarabine 7belantamab mafodotin 6dexamethasone acetate 5dexamethasone 21-phosphate 5auricularum 5X-Rays 5tocilizumab 4selinexor 4fludarabine phosphate 4elotuzumab 4Nuclear Medicine Department, Hospital 4trametinib 3dabrafenib 3Whole-Body Irradiation 3Thalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × Leflunomide × 30 days × Clear all
NCT04508790 2026-05-29

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

City of Hope Medical Center

Phase 2 Recruiting
29 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡